Do rosuvastatin cause weight gain
Pro Research Analysisby 
Searched over 200M research papers
Rosuvastatin and Weight Gain: Analyzing the Evidence
Introduction to Rosuvastatin and Its Effects
Rosuvastatin, a widely used HMG-CoA reductase inhibitor, is primarily prescribed to manage hyperlipidemia and prevent cardiovascular diseases. However, its impact on body weight, particularly whether it causes weight gain, is a topic of interest and concern for many patients and healthcare providers.
Rosuvastatin and Weight Gain in Animal Studies
Several studies have investigated the effects of rosuvastatin on body weight in animal models. A study on C57Bl/6 mice fed a high-fat diet (HFD) demonstrated that rosuvastatin treatment decreased adiposity and adipocyte size, suggesting a reduction in fat accumulation rather than weight gain . This study also found that rosuvastatin altered fat distribution, favoring subcutaneous over visceral fat, which is generally considered a healthier fat distribution pattern .
In another study involving female Wistar rats treated with oral contraceptives and a high-fat diet, rosuvastatin did not prevent weight gain, although it did improve lipid profiles by inhibiting significant rises in triglycerides and total cholesterol levels . This indicates that while rosuvastatin may not directly cause weight gain, it also does not significantly prevent it in the context of a high-fat diet and hormonal treatments.
Rosuvastatin's Metabolic Effects
Rosuvastatin's impact on metabolic parameters has been extensively studied. Research on obese dyslipidaemic mice showed that rosuvastatin did not affect weight gain but did improve blood pressure variability and insulin sensitivity, suggesting beneficial metabolic effects independent of weight changes . Additionally, another study highlighted that rosuvastatin improved glucose intolerance and insulin sensitivity in a dose-dependent manner, further supporting its positive metabolic effects without directly influencing body weight .
Pharmacokinetics and Obesity
The pharmacokinetics of rosuvastatin can be influenced by obesity. A study on rats with high-fat diet-induced obesity found that obesity decreased the hepatic uptake of rosuvastatin, leading to higher blood concentrations of the drug . This suggests that while rosuvastatin's efficacy might be altered in obese individuals, there is no direct evidence linking it to weight gain.
Conclusion
The current body of research indicates that rosuvastatin does not cause weight gain. In fact, it may reduce fat accumulation and improve metabolic profiles in various animal models. While it does not prevent weight gain in all contexts, its primary benefits lie in its ability to improve lipid profiles, insulin sensitivity, and fat distribution. Therefore, patients concerned about weight gain while on rosuvastatin can be reassured that the drug is unlikely to contribute to this issue and may offer several metabolic benefits.
Sources and full results
Most relevant research papers on this topic
Pleiotropic effects of rosuvastatin on the glucose metabolism and the subcutaneous and visceral adipose tissue behavior in C57Bl/6 mice
Rosuvastatin improves glucose intolerance, insulin sensitivity, and non-alcoholic fatty liver disease, and shifts fat distribution from visceral to subcutaneous depots in a mouse model of diet-induced obesity.
Rosuvastatin increases vascular endothelial PPARgamma expression and corrects blood pressure variability in obese dyslipidaemic mice.
Rosuvastatin effectively normalizes blood pressure and its variability in obese dyslipidaemic mice, with potential vasculoprotective effects due to increased PPARgamma and SOD1 expression in endothelium.
Tailoring of Rosuvastatin Calcium and Atenolol Bilayer Tablets for the Management of Hyperlipidemia Associated with Hypertension: A Preclinical Study
Bilayer rosuvastatin calcium and atenolol tablets effectively treat coexisting dyslipidemia and hypertension, reducing lipid profiles, slowing weight gain, and lowering blood pressure to normal levels in preclinical studies.
Rosuvastatin displays anti-atherothrombotic and anti-inflammatory properties in apoE-deficient mice.
Rosuvastatin has anti-inflammatory and anti-atherothrombotic properties in apoE-deficient mice, potentially benefiting atherogenesis.
Ascorbic acid co-administered with rosuvastatin reduces reproductive impairment in the male offspring from male rats exposed to the statin at pre-puberty.
Ascorbic acid supplementation co-administered with rosuvastatin reduces reproductive impairment in male offspring caused by statin treatment to fathers.
DOI